The origins of the current genetic model of cancer initiation are complex and many discoveries made all along the 20th century led to this paradigm: mutagenic actions of chemical and physical agents, oncogenic viruses and proto-oncogenes, recurrent chromosomal alterations in some cancers, cancer predispositions linked to mutated tumor suppressor genes, etc. Nevertheless, the article by Nowell in 1976 establishing the model of stepwise selection from an initially normal cell of more and more aggressive subclones thanks to genetic "lability" can be considered as a milestone.
1 Then the genetic model for colorectal tumorigenesis published in 1990 by Fearon and Vogelstein where the disease is the result of the accumulation of specific genetic alterations appearing in a precise order 2 finally produced the current model. In this model, the accumulation of driver mutations, defined as somatic mutations in cancer genes conferring a clonal advantage and thus positively selected for during cancer evolution and causally implicated in oncogenesis, produces malignant clones from a mutated single cell. 3 Linear and branching evolution resulting from mutation and competition between subclones shapes the clonal architecture of the tumor depending on environmental selection pressures.
Troubles in the Prevalent Cancer Theory: Genetic Heterogeneity and Role of the Microenvironment
Based on this fundamental role of genetic alterations and the progress of high-throughput sequencing, cancer genome sequencing projects such as The Cancer Genome Atlas and The International Cancer Genome Consortium were launched by the end of the 2000s to explore cancer genomic alterations and their diversity. Big hopes came with these big projects: the cancer genome was supposed to clarify and finally help to understand the principles of the disease, as well as improve the detection, diagnosis, treatment and possibly prevention of the disease. 4 Of course great lessons were soon possible, 5 especially on the importance of genes involved in cell signaling, epigenetic regulation, RNA splicing, protein homeostasis or metabolism, and there is no doubt that cancer genome sequencing will continue to bring biological, evolutionary and therapeutic insights on cancer. One of the main striking facts revealed by these projects is the variability of the prevalence of somatic mutations between and within cancer classes, ranging from about 0.001 to >400 per megabase (Mb). 6 Childhood cancers and hematological diseases globally carried fewest mutations whereas cancers related to known mutagenic exposures such as lung (tobacco smoking) and malignant melanoma (exposure to ultraviolet light) exhibited the highest prevalence. But in each class, about two to three orders of magnitude are systematically observed between the less and the more mutated tumors, 6 revealing high intertumoral heterogeneity in terms of mutation prevalence.
The total number of simple somatic mutations observed in all of tumor types has grown exponentially since 2011 and tens of millions are now described in databases. Among this huge number, identification of genes containing driver mutations allows establishing the "cancer gene census" 7 where about 600 key cancer genes are now listed. When examining nonsynonymous mutations, the total number per tumor drops between five and few hundreds, 8 indicating that driver mutations are far less abundant, even if synonymous mutations can also act as driver mutations. 9 Analysis of breast cancers provides a detailed example of the landscape of cancer genes. By examining the genomes of 100 breast tumors (oestrogen receptor positive or negative) for somatic copy number changes and mutations in the exons of protein-coding genes, Stratton and coworkers found in 2012 driver mutations in at least 40 cancer genes and 73 different combinations of mutated cancer genes. 10 Thus driver mutations are operative in many cancer genes but these results already highlighted the substantial genetic diversity underlying breast cancer, with many infrequently mutated genes collectively making a substantial contribution in myriad different combinations. The patterns of somatic mutation in primary triple-negative breast cancers revealed that some genes (TP53, PIK3CA and PTEN) seem to be dominant compared to other genes, 11 but also that their clonal frequencies are incompatible with founder status in some tumors, raising fundamental questions about what drives early clonal expansion. No common initial genetic event was identifiable.
Recently, a more complete landscape of somatic mutations in breast cancer was obtained thanks to 560 whole-genome sequences. 12 By incorporating recurrent copy number changes, a total of 1,628 likely driver mutations in 93 cancer genes was generated, with at least one driver identifiable in 95% of cancers (5% remained to be linked to such mutations). Although the 10 most frequently mutated genes, especially TP53, accounted for 62% of driver mutations, a long tail of the frequency distribution is observed. A similar result is obtained when analyzing the sequenced exomes and whole genomes of 11,119 human tumors representing 41 tumor types to detect somatic substitution hotspots. 13 Indeed 85% of all hotspots were mutated in <5% of tumors of all types in which they were found. Moreover, many hotspots present at low frequency across cancers are not mutated commonly or significantly in even a single cancer type. Thus, although a few drivers seem to be likely contributors to the development of cancer, most of the mutations form a confusing mix of unusual genetic events, with little commonality between tumors, revealing a need for analyzing functions rather than continuing to accumulate sequences, especially when observing for instance that diverse genetic and epigenetic alterations converge phenotypically into four main breast cancer classes.
14 As strikingly different mutations recurrently hijack the same hallmark molecular pathways and networks, novel initiatives such as the Cancer Cell Map Initiative 15 aim at defining the hallmark networks of cancer.
Nevertheless, more confusion appears when observing that the same driver mutations and pathways do not produce the same myeloproliferative neoplasms depending on their order of appearance, 16 or the same glioblastoma subtype 17 or frequency of malignant mammary tumors 18 depending on the tumor cell of origin. But the most striking results when considering the initial role of genetic alterations are those showing that precancerous lesions such as Barrett's esophagus sometimes (25%) show no cancer-related genomic changes, suggesting that they initiate without driver mutations. 19 Clinically defined precancerous lesions can clearly arise in the absence of established driver mutations, again prompting rethink about what drives initial expansion. Genetic alterations might enhance, but not ensure, tumoral transformation. 19 Intratumoral heterogeneity (ITH) is another issue for the current genetic model of cancer. Thanks to multiregional sequencing, variations of the ITH degree are observed among tumors of the same type, what is correlated to the tumor size, 20 different tumor types being also associated with different degrees of ITH. As sequencing of 100 single cells from a polygenomic tumor revealed three distinct clonal subpopulations that probably represent sequential clonal expansions, 21 this ITH likely results from branched evolution because tumor subpopulations are each distant from their root, without observable intermediate branching. But more problematic is the absence of evidence for positive Darwinian selection observed in a hepatocellular carcinoma where an extremely high genetic diversity was found among about 300 sequenced or genotyped regions. 22 In the prevailing Darwinian view of tumor development, selection for and against new mutations would reduce genetic diversity in the range of tens to hundreds of coding region mutations within the whole tumor. On the contrary, this study revealed by high-density sampling in a single tumor an estimated number of millions of mutations, most of which being present at low frequencies. Thus clonal diversity implies evolution under a non-Darwinian mode in this case because the genetic diversity would be far less important (several orders of magnitude) under the classical Darwinian mode. Nevertheless, using the terms "clonal diversity" is still possible here while single-cell sequencing performed on a clear cell renal cell carcinoma indicates that this tumor did not contain any significant clonal subpopulations, 23 suggesting an absence of clonal expansion and calling into question the genetic origin of the disease.
Other difficulties are highlighted when the microenvironment is shown to directly act as tumor inducer or repressor. The sole tissue disruption has been able to produce tumors in many experimental models, especially in leukemogenesis. [24] [25] [26] [27] It is suggested that "field cancerization" arises when the relationships between the epithelial tissue and the stroma are compromised because signaling from stromal cells is disrupted. 28 On the contrary, a native microenvironment suppresses the
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Capp cancerous phenotypes to allow normal development either from mosaic blastocysts where teratocarcinoma cells were injected 29 or from an enucleated oocyte where a melanoma nucleus was transplanted. 30 Similar results are observed during developmental regeneration of mouse mammary gland 31, 32 : human cancer cells differentiate and lose their tumorigenic potential when exposed to tissue-specific cues suggesting that cancer cells can be environmentally controlled in situ by signals generated within developing tissues.
These few results represent only a small sample of the large body of historical evidence that emphasized functional analysis rather than accumulation of genetic sequences. 33 For instance in vivo experiments performed on rat hepatocarcinoma cell lines transplanted in genetically identical rats analyzed the controlling effects of normal tissues over cancer cells. [34] [35] [36] An experimental system was developed allowing analyzing the interacting roles of cellular genotype and tissue microenvironment in the development of tumors, including age dependency of tumor development. While all studied cell lines formed tumors when injected subcutaneously or intraperitoneally whatever the age of the recipient animals, young rats intrahepatically transplanted rapidly produce small tumors at the site of inoculation but these tumors regress within 1 month of their formation. 35 The same cells transplanted into old rats in the same location quickly produce expanding liver tumors that kill the host. 34 Thus the hepatic microenvironment regulates the proliferation and differentiation of neoplastically transformed and genetically aberrant hepatic cells, thereby eliminating or reducing their tumorigenic potential. Aneuploid tumorigenic cells can be normalized by epigenetic influences, but this regulatory potency of the liver microenvironment declines with advancing age. 36 Moreover, the importance of cell-cell interactions is revealed by these studies because normalized cells revert to an undifferentiated, tumorigenic phenotype upon removal from the liver and dissociation, 36 indicating that the tissue microenvironment has a determining role in mediating the phenotype expressed by these genetically aberrant cells.
Normalization of cancerous cells by co-culturing them with normal cells has also been described many times. 37 Finally, the presence of multiple mutations in normal tissues is known for a long time, 38 but recent results highlighted the high density of mutated clones with oncogenic alterations in the normal skin, 39 demonstrating the controlling ability of the microenvironment over cells containing driver mutations. The evidence of widespread, low frequency, age-associated somatic TP53 mutation in the peritoneal fluid of patients with and without ovarian cancer 40 also provides evidence for the emerging concept that somatic mutations in classically cancer-associated driver genes occur in noncancerous normal tissues. 41 Finally, microenvironmental and epigenetic contributions to cancer development are supported when considering evidences for selection as the driving force in neoplastic development. For instance, passage of newly explanted cells at high density select for increased transformation. 42 Also emergence of both spontaneous transformants and transformants induced by mutagenic agents is facilitated by selective growth conditions, as compared with non-selective growth conditions. 43 This is also the case for the uniform, non-stochastic selection for preneoplastic cells in saturation density due to multiple endogenous variants of low fitness advantage present in heterogeneous cell population. 44 Their relatively high frequency, regularity of occurrence and uniformity of appearance are characteristic of an epigenetic process. 44 
Non-genetic Heterogeneity and Role of Stochastic Gene Expression
Apart from the genetic level, non-genetic heterogeneity is also revealed when analyzing gene expression profiles in single cancer cells, 45 for instance from primary glioblastoma where subpopulations with distinct and very different transcriptional profiles are observed, 46 the degree of heterogeneity having profound implications for the clinical outcome. In some cases, this diversity generates a continuum of phenotypic states demarcated by gradients of marker expression rather than distinct subpopulations. 47 This non-genetic heterogeneity clearly impacts cancer growth and therapy tolerance. In colorectal cancers, the functional variability of tumor cells not caused by the genetic level might originate from epigenetic variations, gene expression noise or variations of the microenvironment. 48 Especially epigenetic alterations are commonly observed in cancer and contribute to the hallmarks of cancer. 49 Their role in diversifying phenotypes is generally admitted in cancer progression, but they are not frequently evoked in early steps. Nevertheless, the idea that constitutional epimutations might cause cancer as genetic predispositions do, 50 or that cancer might originate from progenitors where epigenetic alterations first appear, 51 shows the possible epigenetic contribution to cancer initiation. Recent works highlighted the presence of widespread DNA methylation defects in normal tissues adjacent to breast cancers, what is consistent with the causal role of epigenetics and a model where genetic alterations come later in the progression to cancer. 52 Alterations in DNA methylation stochastically appear during transformation through a passive process where local and uncorrelated changes are not the result of an orchestrated reprogramming the epigenome. 53 Moreover, oncogenesis is accompanied by a profound remodeling of the epigenome resulting in a loss of developmental information and a reversion of the chromatin to a more primitive state sharing features with embryonic stem cells. 54 Undifferentiated are characterized by open and highly accessible chromatin, while differentiation is associated with a progressive closing. 55 This accessibility generates global and stochastic gene expression (SGE) (high gene expression noise) which is a hallmark of pluripotency, 56 suggesting that the pluripotent state would be better described as a statistical property of cell populations because its intrinsic variability does not allow to well-define it at the single-cell level. 57 On the contrary, commitment is associated with reduction of the expressed portion of the genome, 56 with a probable spatiotemporal regulation of the variability during normal development in vivo. Thus the permissive chromatin architecture is progressively more constrained to produce a restrictive chromatin giving stable expression patterns and well-defined phenotypes. 57 The main questions concern the nature of these constraints, and what happens when they are released.
Tissue Disruption and Enhanced Stochastic Gene Expression
Many aspects of the relationship between gene expression and tissue structure have been reviewed into the details, for instance the influence of the extracellular matrix, 58 especially in the context of morphogenesis. But recent works now give evidence that a degree of coordination of stochastic gene expression is affected by tissue structure. Indeed, many examples of reduction of gene expression noise and progressive coordination of gene expression profiles from cell-to-cell in tissues during development can be found in the literature. For instance, in 2011, cell differentiation has been tracked for the first time in vivo during development in intact tissues using live-cell imaging to quantify reporter gene expression. 59 Single-cell transcriptional activity in living tissue was visualized using imaging of pituitary tissue from transgenic rats in which luciferase was expressed from the prolactin (a pituitary hormone) promoter. 60 Spatiotemporal analysis among the first endocrine cells that appeared showed highly pulsative expression which is then stabilized as tissue develops and cell number increases. The stabilized expression pattern depends on the tissue architecture and cellular interactions because the same cells harbored pulsative and heterogeneous luminescence when dissociated. It was the first demonstration of a progressive coordination of a differentiation gene during development in living cells and intact tissue.
Recently, the same group revealed that direct cell contacts involving gap junctions allowed local spatial coordination of prolactin gene expression in pituitary adult tissue. 61 Moreover, trypsin-mediated digestion of extracellular proteins or pharmacological inhibition of intercellular gap junctions reduced transcriptional coordination between cells in the adult gland, 61 showing that perturbation of cell communication can enhance SGE and phenotypic heterogeneity among differentiated cells. Nevertheless, other processes dampen the intrinsic variability of gene expression in normal tissues. For instance, polyploid hepatocytes were recently shown to exhibit less noise than diploid hepatocytes, while the average expression of genes was mostly unchanged. 62 This study suggested a possible benefit of polyploidy-reducing gene expression noise, with the intriguing hypothesis that liver polyploidization may counteract the agerelated noise increase. This result might be of importance in cancer because the behavior of clonal masses of often aneuploid cells may be different from structured mixtures of normal cell types in terms of noise-induced phenotypic heterogeneity.
In Drosophila, the expression noise of the transcription factor Yan responsible for maintaining eye cells in a multipotent state is transiently increased as cells transited to differentiation. 63 Signals received from the EGF receptor are necessary for the transience and for eye cells to differentiate so that eye differentiated cell states are stabilized through noise reduction of Yan. 63 Thus the authors suggested that dynamic heterogeneity of Yan is a necessary element of the transition process, and that cellular communications are essential in stabilizing and homogenizing gene expression during cell differentiation. A similar mechanism was already described in C. elegans embryos where the absence of some Frizzled receptors activating the Wnt pathway increases mab-5 expression variability in Q neuroblasts. 64 This increased noise generates mispositioning and disrupts differentiation of some daughter cells. Thus strong Wnt signaling is essential to maintain low mab-5 expression variability and to ensure reliable neuroblast development. Nevertheless, the most conclusive evidence about the primary role of SGE to diversify phenotypes followed by stabilizing and homogenizing signaling resulting from cellular interactions comes from studies on the early mouse blastocysts. 65 An initial phase of stochastic expression of individual genes precedes signal reinforcement through Fgf4 that segregates epiblast and primitive endoderm lineages.
Tissue structuring decreases gene expression noise thanks to the establishment of cell-cell interactions and subsequent intracellular signaling. Thus these interactions possess all the necessary features to constitute the constraints that progressively make the chromatin transit from a permissive to a restrictive state during cell commitment. 57 Considering that dedifferentiation and acquisition of stem-like properties are key features of the tumoral process, oncogenesis seems to be possible in this scheme through removal of these constraints established during differentiation. Disruption of the cellular interactions that stabilize phenotypes and homogenize gene expression patterns would produce cancer stem cells (CSC) defined as cells with increased SGE that are no more controlled by the cellular microenvironment. 66 Cancer initiation would be entirely possible through alteration of cellular membranes, cellular junctions, adhesion molecules or soluble molecules like hormones or growth factors (which constitutes an indirect mode of interaction) for instance. In that case, differentiation and quiescence would no longer be maintained because of the stochastic nature of gene expression, and genetic and epigenetic instabilities would necessary appear, increasing the risk of malignant transformation. Selection of genetic and epigenetic alterations would depend on the selective pressure in the tissue. A similar phenomenon starting from normal cell that fail to set up cellular interactions during the differentiation process would produce "non-controlled" stem-like cells with the required phenotypic plasticity to produce tumors.
Resolution of Paradoxical Situations
The major role of genetic modifications in cancer progression is absolutely not denied in this model, but micro-environmental and epigenetic alterations would precede the emergence of cancer. If genetic alterations are already present in the cells because of mutagenic exposure, cancer predisposition or spontaneous mutations, precancerous cells would become more aggressive more rapidly, increasing the probability that a tumor forms, but only if the correct tissue microenvironment is not maintained. The classical perspective is reversed: disruption of tissue equilibrium is the initial event, and genetic alterations are promoting and accelerating factors. The absence of driver mutations in precancerous lesions 19 or clonal mutation in primary tumors 23 is not surprising in this scheme, neither the presence of epigenetic alterations that precede cancer development 52 nor the diverse abilities of the micro-environment to produce or suppress the cancerous state (see above). The high inter-and intratumoral genetic heterogeneity is also fully comprehensible. The current "micro-environmental" perspective also considers cancer development mainly as a tissue event, but the genetic origin of cancer is generally not taken into question: genetically "initiated" cells must preexist in the tissue to produce tumors. But this idea does not allow integrating all the data listed here while considering cancer initiation at the tissue level without the need of driver mutations does.
Many other paradoxes in the genetic model of cancer initiation would be solved by this alternative model, 67 especially concerning the CSC model. This model remains relatively confused today, with problematic facts regarding their origin, features and frequency. One of the most striking results comes from melanoma cell populations where, depending on the method of isolation and culture, up to 25% of cancer stem cells were identified, showing the role of the environment where cancer cells proliferate in producing stemness. 68 Moreover, no specific molecular marker was revealed, so that their molecular identity remains elusive. It has been suggested that cancer stem cells might be extrinsically induced by the micro-environmental conditions rather than intrinsically produced by mutations in self-renewal genes and other genes specific to stem cells. 69 The model presented here makes these data coherent if considering that the stem state is acquired if any disruption of the tissue equilibrium destabilizes well-differentiated cells or progenitor cells during their commitment.
Conclusion
Finally if cancer cells are mainly characterized by their destabilized gene expression pattern and their widespread SGE that find their origin at the tissue level, only a therapeutic strategy able to restore cellular interactions similar to those taking place in normal tissues would overcome this intrinsic instability. 70, 71 It might be the sole way to counteract the genetic heterogeneity among cancer cell populations and the plasticity of each cancer cell together allowing escape in face of the most sophisticated therapies. Nevertheless, to achieve cancer cell "re-stabilization" or "normalization," genes involved in cell differentiation and cellular interactions must be re-expressed, making epigenetic drugs 72 good candidates as a part of this strategy. 70 Nevertheless, the sole expression of these genes would not be sufficient because of the lack of extracellular ligands that would mimic the normal microenvironment. The relative inefficiency of epigenetic drugs to generate differentiation might be due to the need to introduce in combination to them molecules that are able to interact with the re-expressed proteins to produce intracellular signaling. Only this two-step strategy would stabilize the re-expressed genes and suppress the cancerous state by decreasing SGE.
